Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis

Summary

The purpose of this study is to investigate the effect of AZD5069 in patients with bronchiectasis.

Timeline

Start

2011-02

Primary completion

2012-02

Completion

2012-02

Outcome

Met primary endpoint

registry analysis (superiority or other test); AZD5069 vs Placebo; p = 0.004; Ratio of AZD5069 80 mg to placebo 0.31 (90% CI 0.17 to 0.59); ANCOVA NCT01255592 ↗

Drugs

Indications